Abstract
Purpose
Gastrointestinal stromal tumors (GIST) have the potential to recur and metastasize. Several prognostic schemes have been developed but none are precise enough and most times the pathologist faces a small biopsy where it is not possible to evaluate the mitotic count. Our aim was to determine the influence of ki67 index and other clinicopathologic characteristics in the recurrence of GIST.
Methods
Forty-three consecutive cases of GIST were studied. The cases presented with non-metastatic disease. We compared the clinicopathologic features of cases with recurrence against those with non-recurrence. The ki67 index was determined by square-millimeters.
Results
The median age was 55 years (IQR 45–63), the most frequent site of involvement was the stomach with 21 (48.8%) cases, and the median of tumor diameter was 10 cm (IQR 5.5–17.5). Twenty-six (60.5%) cases were spindle cell, 13 (30.2%) were mixed, and 4 (9.3%) were epithelioid. The median mitosis count for 50 high power fields was 4 (IQR 0–16), while per square millimeter it was 1 (IQR 0–5, range 0–32). The median of the ki67 proliferation index was 5% (IQR 1–20). During the period of study, 11 (25.6%) patients recurred. The only significant differences between patients with GIST with recurrence and without recurrence were the sex and tumor size.
Conclusion
We did not find an association of the ki67 index with recurrence. The factors associated with recurrence were a high tumor size (> 10 cm) and male sex.
Abbreviations
- GIST :
-
Gastrointestinal stromal tumor(s)
- HPF :
-
High-power field
- HR :
-
Hazard ratio
- IQR :
-
Interquartile range
- NIH :
-
National Institute of Health (USA)
- ROC :
-
Receiver operating characteristic
- USA :
-
United States of America
References
Kjetil S, Sandvick O, Soreide J, Giljaca V. Global epidemology of gastrointestinal stromal tumours (GIST): a systematic review of population based cohort studies. Cancer Epidemiol. 2016;40:39–56.
Das neves O, Oshima C, Artigiani-neto R, Yanaguibashi G, Lourenço L. Forones N. Ki67 and p53 in gastrointestinal stromal tumors – GIST. Arq Gastroenterol. 2009;46:116–20.
Zhao W-Y, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol. 2014;7(5):2298–304.
Seidal and Edvardsson. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology. 1999;34(5):416–24.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.
Cerski MR, Pereira F, Matte US, Oliveira FH, Crusius FL, Waengertner LE, et al. Exon 11 mutations, Ki67, and p16(INK4A) as predictors of prognosis in patients with GIST. Pathol Res Pract. 2011;207:701–6.
Di Vizio D, Demichelis F, Simonetti S, Pettinato G, Terracciano L, Tornillo L, et al. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer. 2008;8:134.
Toquet C, Le Neel JC, Guillou L. Elevated (>or=10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumours patients: a study of 35 cases. Dig Dis Sci. 2002;47:2247–53.
Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, Chhieng DC. Prediction of aggressiveness of gastrointestinal stroma tumors based on immunostaining with bcl-2. Ki67 and p53. Cytopathology. 2007;18:283–9.
Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213–20.
Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000;24:1339–52.
Kramer K, Knippschild U, Mayer B, Bögelspacher K, Spatz H, Henne-Bruns D, et al. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer. 2015;15:57.
Author information
Authors and Affiliations
Contributions
PSR and LSLS conceived of the study, and performed the interpretation of immunohistochemistry and pathological analysis. PSR, LSLS, and EAC retrieved clinical data. All authors participated in its design and coordination and helped to draft the manuscript. LSLS and RASH performed de statistical analysis. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics Approval and Consent to Participate
This study was conducted following the statements of Helsinki declaration and was approved by the Ethics in Investigation Board of our Institution with a waiver of informed consent (approval number Rev/70/17).
Consent for Publication
This work does not contain data that could identify any individual in any way, but a waiver of informed consent was obtained.
Competing Interests
The authors declare that they have no competing interests.
Declaration of Authorship
All authors meet the criteria for authorship as per the guidelines of the International Committee of Medical Journal Editors (ICMJE), all have participated at: (1) conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; (2) drafting the work or revising it critically for important intellectual content; (3) final approval of the version submitted; and (4) agreement to be accountable for all aspects of the work regarding the accuracy or integrity of the research.
Rights and permissions
About this article
Cite this article
Segales-Rojas, P., Lino-Silva, L.S., Aguilar-Cruz, E. et al. Association of ki67 Index with Recurrence in Gastrointestinal Stromal Tumors. J Gastrointest Canc 49, 543–547 (2018). https://doi.org/10.1007/s12029-018-0150-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-018-0150-z